ATG Versus Basiliximab in Kidney Transplant Displaying Low Immunological Risk But High Susceptibility to DGF

NCT02056938 · clinicaltrials.gov ↗

PHASE4

Phase

TERMINATED

Status

19

Enrollment

OTHER

Sponsor class

Stopped recruitment issues

Conditions

Kidney Transplantation

Interventions

DRUG: Anti-Thymocyte Globulins treatment
DRUG: Basiliximab treatment

Sponsor

Nantes University Hospital